海外の治験の状況「COVID-19」での検索結果
70件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- A Randomized, Parallel Group, Double-Blind, Placebo Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects with Rheumatoid Arthritis Having an Inadequate Response to Methotrexate. Pharmacogenetics Blood Sample Amendment 01 (version 1.0, dated 19-Dec-2007); Revised Protocol 01, incorporating administrative letter 01 and amendment 03 (version 1.0, dated 12-Mar-2008)
- subjects with rheumatoid arthritis (RA) who are on background therapy with methotrexate (MTX) MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis
- Czech Republic, France, Spain
- 2008-04-15
Authorised
- A phase III, observer-blind, multicountry, multicentre study to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals’ GSK2186877A influenza vaccine administered to adults aged 66 years and older compared to Fluarix™ administered to adults aged 19-43 years and 66 years and older, who previously participated in the 111737 study. - FLU NG-039 EXT: FLU-AS25-025 Y2
- Immunization against influenza in male and female subjects aged 19-43 years and 66 years or older.
- Germany, Netherlands, Sweden
- 2009-07-02
Not Recruiting
- A phase II, open, non-randomized study designed to evaluate the reactogenicity and immunogenicity of one or two booster administrations of an influenza pandemic candidate vaccine (GSK1562902A) in adults aged between 19 and 61 years, previously vaccinated with 2 doses of a pandemic candidate vaccine H5N1 A/Vietnam/1194/2004 containing 3.8, 7.5, 15 or 30 µg HA, adjuvanted or not with AS03. - H5N1-015
- Since 1997, avian H5N1 influenza has caused several human infections and high mortality rate in Southeast Asia. Experts warn that the next influenza pandemic is imminent and could be severe. Prevention and control will depend on the rapid production and worldwide distribution of specific pandemic vaccines. Candidate ‘pandemic-like’ vaccines must be developed and tested in clinical trials to determine the best vaccination schedule.
- Belgium
- 2007-07-03
Authorised
- Phase IIIb Multicenter, Single Arm, Open-label Pilot Study to Evaluate the Effectiveness and Safety of Maintenance with Atazanavir/ritonavir as Single Enhanced Protease Inhibitor Therapy in HIV-Infected Patients Evidencing Virologic Suppression. Revised Protocol 01, incorporating Protocol Amendment 01 (Version 1.0, Date 19-Jan-2007). Estudio piloto de fase IIIb, de un solo brazo, abierto y multicéntrico, para evaluar la eficacia y la seguridad del mantenimiento con atazanavir/ritonavir en monoterapia en pacientes infectados por el VIH que muestren supresión virológica. Protocolo Revisado 01, que incorpora la enmienda 01 al protocolo (v 1.0 de fecha 19-enero-2007). - OREY
- HIV-Infected Patients Evidencing Virologic Suppression Pacientes infectados de VIH, con supresión virológica evidente
- Spain
- 2010-03-12
Authorised
- Essai randomisé, en double aveugle, chez les femmes ménopausées ayant un cancer du sein RE+ comparant deux traitements néo-adjuvants : un anti-aromatase (Letrozole) VS un SERM (Tamoxifène). Effet sur des variables biologiques intermédiaires prédictives de la réponse au traitement
- Le cancer du sein est le cancer féminin le plus fréquent en Europe représentant 28% de tous les cancers féminins. Son incidence y est de l’ordre de 70 pour 100 000 femmes. Sa fréquence est stable (une femme sur 10 actuellement). Il est responsable de 20% de la mortalité par cancer chez la femme mais ce taux commence à se stabiliser dans un certain nombre de pays européens (Hermon C, 1996). MedDRA version: 9.1 Level: LLT Classification code 10006187 Term: Breast cancer
- France
- 2010-08-19
Not Recruiting
- A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or Stage IV Melanoma. Revised Protocol 03, incorporating Protocol Amendment 04 (V1.0, Date 26-Aug-2008), Protocol Amendment 05 (V1.0, Date 20-Nov-2008), and Protocol Amendment 06 (V1.0, date 05-Jan-2009). + Protocol Amendment 07, country specific - Germany (V1.0, date 19-Dec-2008). + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (V1.0, Date 26-Nov-2007).
- MELANOMA MedDRA version: 9.1 Level: LLT Classification code 10025670 Term: Malignant melanoma stage III MedDRA version: 9.1 Level: LLT Classification code 10025671 Term: Malignant melanoma stage IV
- Denmark, France, Germany, Italy
- 2008-01-17
Authorised
- A Sequential Adaptive Phase II/III Multi-Center, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo on a Background of Mycophenolate Mofetil and Glucocorticosteroids in Subjects with Active Proliferative Glomerulonephritis Due to Systemic Lupus Erythematosus (SLE). And Pharmacogenetics Blood Sample Amendment Number 1 - Site Specific (Version 2.0, Date 19-Jan-07).
- IMMUNOSUPPRESSION FOR DISEASE, NOS MedDRA version: 9.1 Level: LLT Classification code 10025139 Term: Lupus erythematosus systemic
- Belgium, France, United Kingdom
- 2007-03-26
Not Recruiting
- A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Subjects With Advanced Non-Small Cell Lung Cancer Revised Protocol 02 incorporating Amendment 03 (version 4.0 dated 01-Sep-09) + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 1.0, dated 19-Mar-08)
- Advanced Non-Small Cell Lung Cancer MedDRA version: 9.1 Level: LLT Classification code 10029514 Term: Non-small cell lung cancer NOS
- France, Germany, Italy, Spain
- 2008-08-07
Not Recruiting
- A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who are Resistant or Intolerant to Imatinib Mesylate. Revised Protocol 05, incorporating Administrative Letters 01, 02, 03 and 04 and Amendments 01, 02, 03 (v1.0, dated 28-Feb-2008) and 04 (v1.0, dated 19-Dec-2008)
- Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia who are resistant or intolerant to Imatinib Mesylate
- Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, Germany, Hungary, Ireland, Italy, Spain, Sweden, United Kingdom
- 2005-06-13